3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
5
Not yet recruiting
3
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
78
Fulvestrant
76
Carboplatin
74
Trastuzumab
71
Capecitabine
69
Letrozole
62
Cyclophosphamide
61
Paclitaxel
60
pertuzumab
52
Specimen Handling
52
Docetaxel
50
abemaciclib
46
ribociclib
44
Anastrozole
35
130-nm albumin-bound paclitaxel
35
trastuzumab deruxtecan
34
Magnetic Resonance Spectroscopy
33
Blood Specimen Collection
33
Tamoxifen
32
sacituzumab govitecan
31
exemestane
31
Biopsy
31
Gemcitabine
30
Epirubicin
29
pyrotinib
28
palbociclib
28
Surveys and Questionnaires
27
Injections
27
Drug Therapy
27
eribulin
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Imlunestrant
×
Breast
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled